ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.956,96
-0,18%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Clovis Oncology Inc (CLVS)

  7. Clovis Oncology Inc (CLVS) News

CLVS

Clovis Oncology (CLVS)

Clovis Oncology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CLVS
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
14/04/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
06/04/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
02/03/202314h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
16/02/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
13/02/202312h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
10/02/202315h49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CLVSClovis Oncology Inc
12/01/202312h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
29/12/202215h36Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CLVSClovis Oncology Inc
13/12/202212h10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
13/12/202212h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
12/12/202212h54Dow Jones NewsClovis Oncology Shares Fall Premarket After Bankruptcy FilingNASDAQ:CLVSClovis Oncology Inc
12/12/202206h18Business WireClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286NASDAQ:CLVSClovis Oncology Inc
16/11/202222h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
09/11/202214h12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CLVSClovis Oncology Inc
03/11/202221h18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
03/11/202221h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
03/11/202221h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
03/11/202221h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
03/11/202221h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
27/10/202223h05Business WireClovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific RetreatNASDAQ:CLVSClovis Oncology Inc
17/10/202209h45Business WireClovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM CongressNASDAQ:CLVSClovis Oncology Inc
04/10/202222h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
03/10/202213h00Business WireTRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM MutationsNASDAQ:CLVSClovis Oncology Inc
21/09/202214h00Business WireClovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply AgreementNASDAQ:CLVSClovis Oncology Inc
13/09/202214h00Business WireClovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian CancerNASDAQ:CLVSClovis Oncology Inc
12/09/202213h55TipRanksClovis (NASDAQ:CLVS) Jumps After Rubraca Shows Progression-Free Survival in Ovarian CancerNASDAQ:CLVSClovis Oncology Inc
11/09/202216h30Business WireClovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk SubgroupsNASDAQ:CLVSClovis Oncology Inc
06/09/202222h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
06/09/202222h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:CLVS

Kürzlich von Ihnen besucht

NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
NYSE
NKE
Nike
TG
MBG
MercedesBenz
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
DAX
DAX
TG
LHA
Deutsche Lufthansa
NYSE
XOM
Exxon Mobil
TG
CBK
Commerzbank
NYSE
JPM
JP Morgan Chase
NYSE
MCD
McDonalds
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
DBI
MDAX
MDAX
DBI
SDXP
SDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten